ANN-LII CHENGQin, ShukuiShukuiQinIkeda, MasafumiMasafumiIkedaGalle, Peter RPeter RGalleDucreux, MichelMichelDucreuxKim, Tae-YouTae-YouKimLim, Ho YeongHo YeongLimKudo, MasatoshiMasatoshiKudoBreder, ValeriyValeriyBrederMerle, PhilippePhilippeMerleKaseb, Ahmed OAhmed OKasebLi, DanengDanengLiVerret, WendyWendyVerretMa, NingNingMaNicholas, AlanAlanNicholasWang, YifanYifanWangLi, LindongLindongLiZhu, Andrew XAndrew XZhuFinn, Richard SRichard SFinn2023-01-122023-01-122022-040168-8278https://scholars.lib.ntu.edu.tw/handle/123456789/627197IMbrave150 demonstrated that atezolizumab plus bevacizumab led to significantly improved overall survival (OS) and progression-free survival (PFS) compared with sorafenib in patients with unresectable hepatocellular carcinoma at the primary analysis (after a median 8.6 months of follow-up). We present updated data after 12 months of additional follow-up.enPD-L1 inhibitor; advanced hepatocellular carcinoma; combination treatment; first-line systemic treatment; overall survival; survival benefit[SDGs]SDG3journal article10.1016/j.jhep.2021.11.030349025302-s2.0-85123615549WOS:000860425300013https://api.elsevier.com/content/abstract/scopus_id/85123615549